Abstract
Recent MR techniques such as breath-hold imaging, fat suppression, and dynamic imaging after intravenous administration of gadolinium chelates have reduced artifacts in the abdomen, resulting in an increased role of MR imaging in the evaluation of pancreatic disease. The extracellular contrast agent gadolinium chelate has been shown to enhance normal pancreatic tissue in a homogeneous fashion. Contrast between normal pancreatic tissue and tumor tissue on T1-weighted images may be improved after administration of gadolinium. Because of the lesser vascularization of pancreatic ductal cancers as compared to the normal glandular tissue, the differences in signal intensity are often greatest in the capillary phase immediately after contrast administration. In addition, the hypervascular nature of islet cell tumors, results in good definition of primary tumor and liver metastases on immediate post-gadolinium images.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Magnetic Resonance Imaging Clinics of North America
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
